Gregory Duncan - Virios Therapeutics Chairman CEO
| VIRIDelisted Stock | USD 3.95 0.00 0.00% |
Insider
Gregory Duncan is Chairman CEO of Virios Therapeutics Llc
| Age | 59 |
| Phone | 866 620 8655 |
| Web | https://www.virios.com |
Gregory Duncan Latest Insider Activity
Tracking and analyzing the buying and selling activities of Gregory Duncan against Virios Therapeutics stock is an integral part of due diligence when investing in Virios Therapeutics. Gregory Duncan insider activity provides valuable insight into whether Virios Therapeutics is net buyers or sellers over its current business cycle. Note, Virios Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Virios Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Gregory Duncan over three months ago Acquisition by Gregory Duncan of 801 shares of Virios Therapeutics at 7.8 subject to Rule 16b-3 | ||
Gregory Duncan over six months ago Acquisition by Gregory Duncan of 138835 shares of Virios Therapeutics at 0.357 subject to Rule 16b-3 | ||
Gregory Duncan over a year ago Purchase by Gregory Duncan of 25000 shares of Virios Therapeutics | ||
Gregory Duncan over a year ago Acquisition by Gregory Duncan of 410000 shares of Virios Therapeutics subject to Rule 16b-3 |
Virios Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.6776) % which means that it has lost $0.6776 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1956) %, meaning that it created substantial loss on money invested by shareholders. Virios Therapeutics' management efficiency ratios could be used to measure how well Virios Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Virios Therapeutics Llc currently holds 358.55 K in liabilities. Virios Therapeutics Llc has a current ratio of 4.66, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Virios Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Nandan BS | Immix Biopharma | 62 | |
| Karen Cashmere | ZyVersa Therapeutics | 72 | |
| M FACP | LMF Acquisition Opportunities | 51 | |
| MBA MD | Immix Biopharma | 49 | |
| Waldemar Priebe | Cns Pharmaceuticals | N/A | |
| CPA CTP | Cns Pharmaceuticals | 44 | |
| Manuel Dafonseca | Sonnet Biotherapeutics Holdings | N/A | |
| Donald Picker | Cns Pharmaceuticals | 78 | |
| Chester III | Revelation Biosciences | 44 | |
| James Rolke | Revelation Biosciences | 55 | |
| Marcel CPA | Altamira Therapeutics | 66 | |
| Qiyong Liu | Transcode Therapeutics | 60 | |
| Anna Moore | Transcode Therapeutics | 62 | |
| MD FACP | Sonnet Biotherapeutics Holdings | 66 | |
| JD MBA | Immix Biopharma | N/A | |
| Dr MedSc | Phio Pharmaceuticals Corp | 68 | |
| Jay Cross | Sonnet Biotherapeutics Holdings | 53 | |
| John Cini | Sonnet Biotherapeutics Holdings | 71 | |
| Covadonga Paeda | Altamira Therapeutics | N/A | |
| David MD | LMF Acquisition Opportunities | N/A | |
| Robert Dudley | Transcode Therapeutics | 73 | |
Management Performance
| Return On Equity | -1.2 | |||
| Return On Asset | -0.68 |
Virios Therapeutics Llc Leadership Team
Elected by the shareholders, the Virios Therapeutics' board of directors comprises two types of representatives: Virios Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Virios. The board's role is to monitor Virios Therapeutics' management team and ensure that shareholders' interests are well served. Virios Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Virios Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gregory Duncan, Chairman CEO | ||
| Carol Duffy, Chief Advisor | ||
| William MD, Founder Director | ||
| Ralph MPH, Senior Operations | ||
| Angela Walsh, SVP CFO |
Virios Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Virios Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.2 | |||
| Return On Asset | -0.68 | |||
| Current Valuation | 1.28 M | |||
| Shares Outstanding | 1.11 M | |||
| Shares Owned By Insiders | 6.74 % | |||
| Shares Owned By Institutions | 3.60 % | |||
| Number Of Shares Shorted | 469.93 K | |||
| Price To Book | 1.37 X | |||
| EBITDA | 150.9 K | |||
| Net Income | (5.3 M) |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Other Consideration for investing in Virios Stock
If you are still planning to invest in Virios Therapeutics Llc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Virios Therapeutics' history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |